TY - JOUR
T1 - Cerebral ischemia and neuroregeneration
AU - Lee, Reggie H.C.
AU - Lee, Michelle H.H.
AU - Wu, Celeste Y.C.
AU - Couto E Silva, Alexandre
AU - Possoit, Harlee E.
AU - Hsieh, Tsung Han
AU - Minagar, Alireza
AU - Lin, Hung Wen
N1 - Funding Information:
1R01NS096225-01A1, the American Heart Association grants AHA-13SDG1395001413, AHA-17GRNT33660336, AHA-17POST33660174, the Louisiana State University Grant in Aid research council, and The Malcolm Feist Cardiovascular Research Fellowship.
Funding Information:
manuscript critically for important intellectual content, and final approval. CYCW, ACS, HEP, THH: drafted manuscript and final approval. AM, and HWL: revised manuscript critically for important intellectual content and final approval. Conflicts of interest: None declared. Financial support: This work was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke grant 1R01NS096225-01A1, the American Heart Association grants AHA-13SDG1395001413, AHA-17GRNT33660336, AHA-17POST33660174, the Louisiana State University Grant in Aid research council, and The Malcolm Feist Cardiovascular Research Fellowship. Plagiarism check: Checked twice by iThenticate. Peer review: Externally peer reviewed. Open access statement: This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Shar-eAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under identical terms. Open peer reviewer: Shasha Li, Harvard Medical School, USA.
Publisher Copyright:
© 2018 Medknow Publications. All rights reserved.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2018/3
Y1 - 2018/3
N2 - Cerebral ischemia is one of the leading causes of morbidity and mortality worldwide. Although stroke (a form of cerebral ischemia)-related costs are expected to reach 240.67 billion dollars by 2030, options for treatment against cerebral ischemia/stroke are limited. All therapies except anti-thrombolytics (i.e., tissue plasminogen activator) and hypothermia have failed to reduce neuronal injury, neurological deficits, and mortality rates following cerebral ischemia, which suggests that development of novel therapies again st stroke/cerebral ischemia are urgently needed. Here, we discuss the possible mechanism(s) underlying cerebral ischemia-induced brain injury, as well as current and future novel therapies (i.e., growth factors, nicotinamide adenine dinucleotide, melatonin, resveratrol, protein kinase C isozymes, pifithrin, hypothermia, fatty acids, sympathoplegic drugs, and stem cells) as it relates to cerebral ischemia.
AB - Cerebral ischemia is one of the leading causes of morbidity and mortality worldwide. Although stroke (a form of cerebral ischemia)-related costs are expected to reach 240.67 billion dollars by 2030, options for treatment against cerebral ischemia/stroke are limited. All therapies except anti-thrombolytics (i.e., tissue plasminogen activator) and hypothermia have failed to reduce neuronal injury, neurological deficits, and mortality rates following cerebral ischemia, which suggests that development of novel therapies again st stroke/cerebral ischemia are urgently needed. Here, we discuss the possible mechanism(s) underlying cerebral ischemia-induced brain injury, as well as current and future novel therapies (i.e., growth factors, nicotinamide adenine dinucleotide, melatonin, resveratrol, protein kinase C isozymes, pifithrin, hypothermia, fatty acids, sympathoplegic drugs, and stem cells) as it relates to cerebral ischemia.
KW - Cerebral ischemia
KW - Fatty acids
KW - Melatonin
KW - Neuromodulation therapy
KW - Pifithrin-α
KW - Protein kinase C
KW - Resveratrol
KW - Stem cell
KW - Sympathetic nervous system
KW - Traditional Chinese therapies
UR - http://www.scopus.com/inward/record.url?scp=85049833023&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049833023&partnerID=8YFLogxK
U2 - 10.4103/1673-5374.228711
DO - 10.4103/1673-5374.228711
M3 - Review article
AN - SCOPUS:85049833023
VL - 13
SP - 373
EP - 385
JO - Neural Regeneration Research
JF - Neural Regeneration Research
SN - 1673-5374
IS - 3
ER -